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High-sensitivity C-reactive Protein Can Predict Major Adverse 
Cardiovascular Events in Korean Patients with Type 2 Diabetes
 Inflammation is thought to play a role in the pathogenesis of major adverse cardiovascular 
events (MACE). It has been suggested that the measurement of markers of inflammation 
may aid in predicting the risk of such events. Here, the relationship between high-
sensitivity C-reactive protein (hs-CRP) levels and MACE in Korean patients with type 2 
diabetes is assessed. A retrospective cohort study was conducted as a follow-up among 
1,558 patients with type 2 diabetes and without cardiovascular diseases over a mean 
period of 55.5 months. A Cox proportional-hazards model was used to determine whether 
increased hs-CRP levels are useful as a predictor for future MACE. The hazard ratio of 
MACE was 1.77 (95% CI; 1.16-2.71) in subjects who had the highest hs-CRP levels 
( > 0.21 mg/dL) compared to subjects who had the lowest hs-CRP levels ( < 0.08 mg/dL), 
after adjusting for age, regular physical activity, current smoking, and duration of 
diabetes. The present results indicate that high hs-CRP levels can act as a predictor for the 
MACE occurrence in Korean patients with type 2 diabetes.
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INTRODUCTION
The presence of diabetes is an independent risk factor for ath-
erosclerosis. Endothelial dysfunction, oxidative stress, and low-
grade inflammation are major features in the pathophysiology 
of this disease (1). It has been shown that atherosclerosis in pa-
tients with diabetes mellitus (DM) can lead to acute coronary 
artery disease, ischemic cerebral disease, and peripheral arteri-
al disease (2). Because atherosclerosis is an inflammatory pro-
cess, several plasma markers of inflammation have been evalu-
ated as potential tools for the prediction of risk for cardiovascu-
lar disease (3). For example, a high serum level of high-sensitiv-
ity C-reactive protein (hs-CRP), a marker of systemic inflamma-
tion and a mediator of atherosclerotic disease, has been corre-
lated with an increased risk for cardiovascular disease (4-6).
  Although it is generally accepted that hs-CRP levels can act as 
a predictor for cardiovascular disease in non-diabetic patients, 
there is a relative lack of data concerning the usefulness of hs-
CRP levels when predicting the occurrence of cardiovascular 
diseases in Asian type 2 diabetic patients. Thus, the objective of 
this study was to clarify the independent clinical value of hs-CRP 
levels in the occurrence of major adverse cardiovascular event 
(MACE) in Korean type 2 diabetic patients.
MATERIALS AND METHODS
Participants and study design
A retrospective cohort study was conducted involving 2,452 pa-
tients between 30-70 yr of age with type 2 diabetes who were 
managed in the Endocrinology Department of Kwandong Uni-
versity Myongji Hospital, Goyang, Korea. Serum hs-CRP levels 
were measured between January 2004 and December 2007 dur-
ing hospital visits prior to the occurrence of MACE. After careful 
history taking and physical examination, 388 subjects were ex-
cluded for the following reasons: previous cardiovascular dis-
eases, type 1 diabetes, pregnancy, breast feeding, acute infec-
tion or chronic inflammatory disease (upper or lower respira-
tory infection, urinary tract infection, acute gastrointestinal in-
fection, inflammatory bowel disease, osteoarthritis, rheumatoid 
arthritis, chronic hepatitis, gout, and bronchial asthma), or high 
baseline hs-CRP levels ( > 1 mg/dL) (7). MACE occurrence was 
identified using an electronic medical record system in the re-
maining 2,064 subjects. All subjects were contacted by phone 
to confirm the occurrence of MACE. If the patients were con-
firmed with MACE but had moved to another hospital, the rel-
evant hospital was contacted so that data could be collected. The 
occurrence and non-occurrence of MACE were confirmed in 
1,766 of the 2,064 subjects. The mean follow-up period was 55.5 
(20-92) months.Lee S, et al.  •  Hs-CRP for Major Adverse Cardiovascular Events
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Baseline measurements and definitions
Blood sampling and hemodynamic measurements were per-
formed on all patients. Levels of hs-CRP were measured using a 
high-sensitivity assay (turbidity immune assay, Toshiba, Tokyo) 
with a detection limit of 0.01 mg/dL. DM was defined as a fast-
ing blood glucose concentration of  ≥ 126 mg/dL or as receiving 
anti-hyperglycemic drug treatment. Body mass index (BMI) was 
calculated by weight in kilograms divided by square of height in 
meters. Height, weight, and plasma levels of hs-CRP, fasting glu-
cose, HbA1c, total cholesterol, triglycerides, and high-density 
lipoprotein (HDL)-cholesterol were measured simultaneously. 
LDL-C was estimated using the equation developed by Friede-
wald et al. (8) Regular physical activity was defined as over 150 
min of exercise per week. 
  Myocardial infarction (MI) was defined according to the guide-
lines of the American Heart Association/American College of 
Cardiology and included elevated cardiac enzymes and specific 
electrocardiogram changes (9). Percutaneous coronary inter-
vention (PCI) was defined as needing percutaneous translumi-
nal coronary angioplasty or stent insertion against significant 
stenosis of the coronary artery. A stroke was defined as rapidly-
developing loss of brain function due to disturbance in blood 
supply to the brain. Additionally, according to the standard World 
Health Organization definition, a stroke is limited to a focal neu-
rological deficit over 24 hr and cerebral hemorrhage on brain 
imaging was excluded (10). Peripheral vascular angioplasty, pe-
ripheral vascular surgery, and amputation due to critical limb 
ischemia were considered to be peripheral vascular events. Car-
diovascular death was limited to the diagnostic code I21-25 or 
I60-73 for the cause of death. Thus, MACE included cases of MI, 
coronary obstructive disease treated by PCI or CABG, stroke, 
other vascular diseases treated by angioplasty or vascular sur-
gery, and cardiovascular death.
Statistical analyses
Several variables, including hs-CRP levels, fasting glucose, HbA1c, 
total cholesterol, triglycerides, HDL-cholesterol, and LDL-cho-
lesterol were not normally distributed in the Shapiro-Wilk test. 
Logarithmic transformation was used to normalize them and 
the variables were applied to the following analysis. A logistic 
regression analysis and a general linear model were used to com-
pare trisected hs-CRP levels and clinical characteristics after ad-
justing for age, sex, and duration of diabetes. The patients were 
divided into two groups according to whether MACE occurred 
or not and the clinical characteristics between the two groups 
were compared through a general linear model and a logistic 
regression analysis after adjusting for age, sex, and duration of 
diabetes. The hazard ratios were estimated for MACE according 
to the tertile of baseline hs-CRP levels after adjusting for age, sex, 
duration of diabetes, current smoking, physical activity, and to-
tal cholesterol by Cox regression analysis.
Ethics statement
The present study was approved by the institutional review board 
(IRB) of Kwandong University Myongji Hospital (IRB approval 
number: 2011-022). The present study was exempted written 
informed consent and all the data collected from this study was 
kept confidential. 
RESULTS
The clinical characteristics of the patients are shown in Table 1. 
The mean hs-CRP level for the 1,766 subjects was 0.21 ± 0.22 mg/ 
dL and the median value was 0.13 mg/dL (interquartile range 
0.05-0.28). Enrolled subjects were divided into three groups ac-
cording to serum hs-CRP level (mg/dL); low (< 0.08 mg/dL), 
medium (0.08-0.21 mg/dL), and high (> 0.21 mg/dL). The low, 
medium, and high hs-CRP levels were 46.2%, 45.8%, and 48.6% 
in women and there was no significant difference of sexual dis-
tribution between the groups. The duration of DM and LDL-
Table 1. Baseline characteristics of the study population
Characteristics
Tertile of plasma hs-CRP level (mg/dL)
P value Low  
( < 0.08)
Medium  
(0.08-0.21)
High  
( > 0.21)
Number 590 593 583
hs-CRP (mg/dL)
a,f   0.04 ± 0.02   0.13 ± 0.04   0.46 ± 0.21 < 0.001
Age (yr)
d   55.5 ± 11.2   56.7 ± 11.2   58.1 ± 11.0 0.001
Gender (% women) 45.8 44.9 48.9 0.624
Duration of DM (yr)   6.0 ± 6.9   5.9 ± 7.0   6.1 ± 7.2 0.545
Smoking (%)
   Current smokers
d
   Past smokers
c
 
23.4
49.2
 
27.7
51.4
 
27.3
50.4
 
0.015
0.056
Physical activity (%)
e 48.3 46.9 38.8 0.003
Weight (kg)
d   63.4 ± 10.4   66.5 ± 11.1   66.4 ± 11.3 < 0.001
BMI (kg/m
2)
a 24.2 ± 2.9 25.3 ± 3.2 25.7 ± 3.6 < 0.001
Systolic BP (mmHg)
b 125.6 ± 17.0 127.9 ± 17.8 127.8 ± 18.0 0.070
Diastolic BP (mmHg)
d   79.2 ± 11.6   81.3 ± 11.6   80.6 ± 12.1 0.002
FBS (mM/L)
a,f   8.45 ± 3.28   8.70 ± 3.09   9.41 ± 3.99 < 0.001
HbA1c (%)
a,f   7.5 ± 2.1   7.9 ± 2.1   8.1 ± 2.2 < 0.001
TC (mM/L)
b,f   4.90 ± 1.04   5.07 ± 1.17   5.08 ± 1.30 0.042
Triglyceride (mM/L)
d,f   1.79 ± 1.36   2.08 ± 1.62   2.19 ± 1.61 < 0.001
HDL-C (mM/L)
b,f   1.19 ± 0.31   1.14 ± 0.34   1.10 ± 0.33 < 0.001
LDL-C (mM/L)
f   2.90 ± 0.97   2.98 ± 1.07   3.00 ± 1.11 0.394
Medication
   ACE-I
   ARB
   Statin
   Aspirin
   Clopidogrel
 
  5.2
20.9
16.2
16.4
  5.1
 
  7.8
17.6
18.6
16.2
  8.2
 
  5.9
19.8
17.1
14.1
  5.9
 
0.176
0.316
0.573
0.246
0.102
Data are expressed as means ± SD and percentages. hs-CRP, C-reactive protein; 
DM, diabetes mellitus; BMI, body mass index; BP, blood pressure; FBS, fasting blood 
glucose; TC, total cholesterol; HDL-C, high-density lipoprotein-cholesterol; LDL-C, low-
density lipoprotein-cholesterol; ACE-I, angiotensin converting enzyme-inhibitor; ARB, 
angiotensin receptor blocker. 
aP value among 3 groups < 0.05. 
bP value of low vs 
medium hs-CRP group < 0.05. 
cP value of low vs high hs-CRP group < 0.05. 
dP val-
ue of low vs medium and low vs high hs-CRP group < 0.05. 
eP value of low vs high 
and medium vs high hs-CRP group < 0.05. P value was estimated by a logistic re-
gression analysis and a general lineal model after adjusting for age, sex, and duration 
of DM. 
fP was calculated from log-transformed data.Lee S, et al.  •  Hs-CRP for Major Adverse Cardiovascular Events
1324   http://jkms.org http://dx.doi.org/10.3346/jkms.2011.26.10.1322
cholesterol level were not different between the groups. The re-
sult showed no significant difference in frequency of angioten-
sin converting enzyme-inhibitors, angiotensin receptor blocker, 
statin, aspirin and clopidogrel administration. However, age, 
weight, BMI, blood pressure, fasting blood glucose, HbA1c, to-
tal cholesterol, and triglycerides increased in proportion to the 
level of hs-CRP. HDL-cholesterol showed an inverse proportion 
to the level of hs-CRP. The percentage of regular physical activi-
ty was low in the high hs-CRP group compared with the other 
groups.
  MACE was observed in 144 patients during the follow-up pe-
riod (mean of 55.5 months). MI was seen in 19 patients; 106 pa-
tients were treated by PCI due to coronary arterial obstructive 
disease, and stroke occurred in 25 patients. All-cause death oc-
curred in 50 patients; 15 of cardiovascular disease, 10 of malig-
nancy, 13 of infectious diseases, 10 of other diseases, and two of 
unknown causes.
  Subjects were divided into two groups according to whether 
MACE occurred or not. Age, duration of DM, current smoking, 
physical activity, total cholesterol, and hs-CRP levels were greater 
in subjects with MACE. There were no significant differences in 
gender, past smoking, BMI, blood pressure, fasting blood glu-
cose, HbA1c, triglycerides, HDL-cholesterol, or LDL-cholesterol 
(Table 2). Compared with the low-level hs-CRP group, the me-
dium- and high-level hs-CRP groups exhibited a trend towards 
an increased risk for MACE in a Cox model (Fig. 1). The crude 
hazard ratio was 1.44 (0.92-2.24) for the medium level hs-CRP 
group and 2.00 (1.31-3.04) for the high level hs-CRP group. After 
adjusting for age, sex, duration of DM, current smoking, physi-
cal activity, and total cholesterol, the relative risk of MACE in-
creased by 77% in the high-level hs-CRP group compared with 
the low-level hs-CRP group (1.16-2.71). The hazard ratio of MACE 
for the medium-level hs-CRP group compared with the low-lev-
el hs-CRP group was not significant (Table 3).
DISCUSSION
 
The aim of this study was to examine the relationship between 
hs-CRP levels and the prognosis of MACE in patients with type 
2 diabetes and without cardiovascular disease. The predictive 
value of baseline hs-CRP levels in the prognosis of MACE was 
Table 2. Baseline demographic data and clinical characteristics of 1,766 subjects 
with MACE versus subjects without MACE
Characteristics
Subjects without 
MACE
Sbujects with 
MACE
P value
Number 1,622 144
Age (yr)   56.4 ± 11.2 61.2 ± 8.9 0.001
Gender (% women) 46.5 45.8 0.109
Duration of DM (yr)   5.7 ± 6.7   9.6 ± 9.4 < 0.001 
Smoking (%)
   Current smokers
   Past smokers
 
25.9
50.5
 
30.6
50.7
 
0.005
0.687
Physical activity (%) 44.9 36.1 0.025
Weight (kg)   65.5 ± 11.1 64.8 ± 9.8 0.467
Body mass index (kg/m
2) 25.1 ± 3.4 25.1 ± 2.9 0.321
Systolic blood pressure (mmHg) 127.1 ± 17.6 126.9 ± 18.1 0.530
Diastolic blood pressure (mmHg)   80.6 ± 11.7   78.0 ± 12.4 0.200
Fasting blood glucose (mM/L)
a   8.85 ± 3.49   9.12 ± 3.66 0.513
HbA1c (%)
a   7.8 ± 2.1   8.0 ± 2.0 0.755
Total cholesterol (mM/L)
a   5.00 ± 1.17   5.20 ± 1.29 0.019
Triglyceride (mM/L)
a   2.00 ± 1.54   2.17 ± 1.53 0.064
HDL cholesterol (mM/L)
a   1.15 ± 0.33   1.11 ± 0.33 0.226
LDL cholesterol (mM/L)
a   2.95 ± 1.05   3.08 ± 1.05 0.131
C-reactive protein (mg/dL)
a   0.21 ± 0.22   0.24 ± 0.21 0.004
Data are expressed as means ± SD and percentage. MACE, major adverse cardio-
vascular event; DM, diabetes mellitus; HDL-C, high-density lipoprotein-cholesterol; 
LDL-C, low-density lipoprotein-cholesterol. P was calculated adjusting for age, sex, 
and duration of diabetes by a general linear model and a logistic regression analysis. 
aP was calculated from log-transformed data.
Table 3. Hazard ratios for MACE according to the tertile of baseline plasma C-reac-
tive protein
Variables
Total  
subjects
Sbujects  
with MACE
Exp(B) P value
CRP tertile
   Low hs-CRP
   Medium hs-CRP
   High hs-CRP
590
593
583
 
33 (5.6)
47 (7.9)
  62 (10.6)
 
1.0
  1.36
  1.77
 
 
0.181
0.009
Covariates
   Age
   Sex
   Duration of DM
   Current smoking
   Physical activity
   Total cholesterol
       
0.001
0.294
< 0.001
0.064
0.042
0.187
Data are are expressed as number (%). MACE, major adverse cardiovascular event; 
DM, diabetes mellitus. P value was calculated by Cox regression analysis.
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(mg/dL)
Follow-up time (months)
Low CRP group
Medium CRP group
High CRP group
  590 (11)  531 (6)  507 (7)  435 (6)  331 (2)  210 (1)  70 (0)    9 (0)
  593 (10)  522 (8)  492 (6)    426 (13) 331 (6)  222 (4)  83 (0)  22 (0)
  583 (13)    514 (13)  475 (12)   405 (11) 300 (9)  192 (4)  79 (0)  24 (0)
-0.07
0.08-0.21
0.22-
  0  12  24  36  48  60  72  84  96
1.00
0.95
0.90
0.85
0.80
Fig. 1. Association between baseline C-reactive protein tertile and a risk for a Major 
adverse cardiovascular event (MACE). Risk estimates were calculated using a multi-
variable Cox regression model, adjusting for age, sex, duration of DM, current smok-
ing physical acitivity, and total cholesterol P value is <0.009 between low-level hs-
CRP and high-level hs-CRP group.Lee S, et al.  •  Hs-CRP for Major Adverse Cardiovascular Events
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lower than that of age or duration of DM, but higher than physi-
cal activity, current smoking, and other conventional risk factors 
for cardiovascular disease.
  Many prospective studies have shown that a high serum con-
centration of LDL-cholesterol is a major risk factor for coronary 
heart disease (11). However, patients with type 2 diabetes show 
a characteristic lipid profile of normal or only slightly raised LDL-
cholesterol (12). Increased small, dense LDL particles may per-
form a more important role during the occurrence of macrovas-
cular complications than the total concentration of LDL-choles-
terol in type 2 diabetic patients (13). Indeed, in some cohorts of 
DM patients, total cholesterol and LDL-cholesterol levels were 
not associated with cardiovascular risk, whereas high triglycer-
ide levels and low HDL-cholesterol concentrations were pow-
erful predictors of coronary heart disease (14). The effect of hy-
pertension in deaths from coronary heart disease is increased 
by 2-5-fold in diabetic patients and the United Kingdom Pro-
spective Diabetes Study confirmed the beneficial effects of im-
proved blood pressure control in type 2 diabetic patients (15). 
However, the present findings showed no difference in baseline 
lipid profiles or blood pressure in patients with or without MACE. 
Currently, the widespread use of lipid-lowering and anti-hyper-
tensive agents in patients with type 2 diabetes may lower the 
value of baseline lipid profiles and blood pressure in the predic-
tion of the risk for cardiovascular disease. Nevertheless, hs-CRP 
levels were more associated with MACE than lipid profiles or 
blood pressure. It is suggested that hs-CRP levels are less affect-
ed by other confounding factors, such as medication, when de-
termining risk of future cardiovascular events in type 2 diabetic 
patients.
  It has been reported that hs-CRP levels are higher in patients 
with type 2 diabetes than in patients without DM (16). However, 
there were differences in the serum hs-CRP levels of subjects 
without diabetes based on ethnicity (17-19). In patients with type 
2 diabetes this same tendency may exist. Mean values of hs-CRP 
levels in type 2 diabetic subjects have been reported to be 0.68 
mg/dL in American Caucasians, 0.11 mg/dL in Japanese, and 
0.19 mg/dL in Chinese populations (16, 20, 21). Median hs-CRP 
levels of Italian patients with type 2 diabetes were reported as 
0.26 mg/dL (22). In the current study, mean and median hs-CRP 
levels in Korean patients with type 2 diabetes were 0.21 mg/dL 
and 0.13 mg/dL, respectively, suggesting that hs-CRP levels in 
European and American Caucasians may be 2-4 times higher 
than in Asian patients. Body weight may be an important factor 
in this difference. The average level of hs-CRP is quite different 
according to BMI and gender of the subjects (23). In fact, body 
weight influenced levels of hs-CRP in the current study and BMI 
ranges of Asian, European, and American patients with type 2 
diabetes mellitus were 24 to 26, 26 to 31, and 31 to 35 in the above-
mentioned reports. Thus, it is important that a clinician consider 
weight and ethnicity when using hs-CRP levels as a marker of 
cardiovascular risk.
  In non-diabetic Caucasians, it is known that hs-CRP levels of 
> 0.3 mg/dL may have predictive qualities (24). In European and 
American type 2 diabetic patients, those with a level of 0.3 mg/
dL or greater had significantly higher relative risks for cardiovas-
cular events, coronary heart disease, and cardiovascular mor-
tality (22, 25, 26). In the present study, the hazard ratio for MACE 
was 1.47 (95% CI; 1.02-2.10) when considering the hs-CRP cut-
off point of  > 0.3 mg/dL. However, this cutoff point for cardio-
vascular disease events is not appropriate for Asian patients with 
type 2 diabetes because only 22.3% of these patients exhibited 
an hs-CRP level of  > 0.3 mg/dL and 69.7% of MACE occurred 
in the low risk group in this study (data not shown). To date, few 
studies have reported findings concerning hs-CRP levels and 
related cardiovascular events in Asian type 2 diabetic patients. In 
Japanese patients with type 2 diabetes, the highest tertile of hs-
CRP levels ( > 0.11 mg/dL) had a relative risk of 1.31 (95% CI: 1.04-
1.67) for all-cause death and cardiovascular events (21). Here, 
the cutoff point for the highest hs-CRP tertile was 0.21 mg/dL 
and higher than that of Japanese patients with type 2 diabetes. 
The difference in BMI between these studies may play a role in 
the findings (25.1 vs 23.7) but ethnic difference must also be con-
sidered.
  It has been reported that the more risk factors for metabolic 
syndrome are clustered, the greater the severity of coronary ar-
tery disease will be (27). This may be applied to the extended dis-
ease concept of MACE. Thus, a global risk assessment for cardio-
vascular disease has meaningful implications for preventing fu-
ture occurrences of MACE. Hs-CRP measurements might pro-
vide information for a global risk assessment for cardiovascular 
disease. Patients with high hs-CRP levels should be made aware 
of an increased risk for MACE and be more closely monitored 
and treated. For patients with coronary artery disease, the re-
duced rate of progression of atherosclerosis associated with in-
tensive statin treatment, compared with moderate statin treat-
ment, is related to greater reductions in the levels of both athero-
genic lipoproteins and hs-CRP (28, 29). Moreover, in Korea, the 
early prescription of statins has been reported to improve prog-
nosis in acute ischemic stroke cases (30).
  Although this study used a large cohort of patients with type 
2 diabetes, there are some limitations. This is a retrospective co-
hort study; thus, some events might be omitted because of errors 
in medical records or patient memories. Secondly, only base-
line data were analyzed in this study and it was not reflected in 
the outcome any change in cardiovascular risk factors and the 
administration of statin, aspirin, anti-platelet agent during the 
follow-up period. Additionally, the fact that baseline hs-CRP 
was not followed up could be also a limitation to analyze the 
outcome. 
  In conclusion, the high-level hs-CRP tertile of  > 0.21 mg/dL 
is independently associated with the future incidence of MACE Lee S, et al.  •  Hs-CRP for Major Adverse Cardiovascular Events
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in Korean patients with type 2 diabetes and without present car-
diovascular disease. But, it did not suggest hazard ratio was pro-
portional to hs-CRP level because the hazard ratio of MACE in 
subjects whose hs-CRP levels were  > 0.3 mg/dL was lower than 
one in subjects whose hs-CRP levels were  > 0.21 mg/dL.
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High-sensitivity C-reactive Protein Can Predict Major Adverse Cardiovascular Events 
in Korean Patients with Type 2 Diabetes
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Markers of inflammation is helpful for predicting the risk of cardiovascular disease. The relationship between high-sensitivity 
C-reactive protein (hs-CRP) levels and major adverse cardiac event (MACE) were compared in 1,558 Korean patients with type 2 
diabetes and without cardiovascular diseases over a mean period of 55.5 months. The hazard ratio of MACE was 1.77 (95% CI; 
1.16-2.71) in subjects who had the highest hs-CRP levels (> 0.21 mg/dL) compared to subjects who had the lowest hs-CRP levels 
(< 0.08 mg/dL), after adjusting for age, regular physical activity, current smoking, and duration of diabetes. 